Gefitinib is widely used to treat NSCLC because of its ability to suppress tumor cell proliferation and promote apoptosis through inhibition of downstream pathways, such as PI3K/AKT and MAPK/ERK [22,23]. This evidence concerns the gene AKT1 and neoplasm.